On Thursday, members of both the U.S. House of Representatives and the U.S. Senate introduced legislation that targets efforts that have limited competition, which keeps the price of prescription drugs high.
The U.S. FDA is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives.
Abbott Laboratories is expected to close during third-quarter 2017 the recently revised deal to buy Alere Inc., calling the diagnostics company “a bit of a fixer-upper.”
Swiss drugmaker Roche Holding has dropped out of a high-profile project to develop an antibiotic for treating “superbug” infections, the company said on Sunday. Roche had agreed in 2013 to pay privately held partner Polyphor up to 500 million Swiss francs ($485.3 million) for rights to the product, marking a rare foray by a […]